home / stock / acst / acst news


ACST News and Press, Acasti Pharma Inc. From 12/13/23

Stock Information

Company Name: Acasti Pharma Inc.
Stock Symbol: ACST
Market: NASDAQ
Website: acastipharma.com

Menu

ACST ACST Quote ACST Short ACST News ACST Articles ACST Message Board
Get ACST Alerts

News, Short Squeeze, Breakout and More Instantly...

ACST - Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal S...

ACST - Acasti Pharma GAAP EPS of -$0.43

2023-11-13 14:32:42 ET More on Acasti Pharma Acasti announces $7.5M private placement equity funding Seeking Alpha’s Quant Rating on Acasti Pharma Historical earnings data for Acasti Pharma Financial information for Acasti Pharma For further de...

ACST - Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA) Highlighted t...

ACST - Expected US Company Earnings on Monday, November 13th, 2023

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

ACST - Expected earnings - Acasti Pharma Inc.

Acasti Pharma Inc. (ACST) is expected to report $-0.29 for Q2 2024

ACST - Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

With achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 Recently announced $7.5 million private placement financing extends projected cash runway to the first calendar quarter of...

ACST - Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (...

ACST - Acasti Pharma director discloses purchase of 676,371 shares

2023-09-28 12:19:12 ET More on Acasti Pharma Acasti announces $7.5M private placement equity funding Seeking Alpha’s Quant Rating on Acasti Pharma Historical earnings data for Acasti Pharma Financial information for Acasti Pharma For further de...

ACST - ACST, TRT and CNTX among mid-day movers

2023-09-27 13:48:39 ET Gainers: ShiftPixy ( PIXY ) +92% . SciSparc Ltd ( SPRC ) +42% . MSP Recovery ( LIFW ) +41% . Biohaven ( BHVN ) +28% . MillerKnoll ( MLKN ) +28% . American Strategic Investment Co ( NYC ) +22% . ...

ACST - APLT, VCNX and FRES among mid-day movers

2023-09-26 13:46:32 ET Gainers: Soleno Therapeutics ( SLNO ) +446% . Femasys ( FEMY ) +271% . Immunovant ( IMVT ) +101% . Intercept Pharmaceuticals ( ICPT ) +79% . Acasti Pharma ( ACST ) +35% . Applied Therapeutics ( APLT ...

Previous 10 Next 10